Analysis of the current status and influencing factors of human papillomavirus vaccination among community women in Longgang District of Shenzhen

Abstract

Abstract: Objective To understand the current status of human papillomavirus（HPV） vaccination and its influencing factors among women in Shenzhen community,and to provide reference for HPV vaccination promotion among women in community. Methods Using a combination of convenience sampling and stratified cluster sampling,1208 women from six street communities in Longgang District,Shenzhen were selected as the survey subjects. A questionnaire survey on the current status of HPV vaccination and its influencing factors was conducted among the sampled population from September to December 2023,and the data were analyzed. Results The average age of the included study subjects was （34.04±9.21）years. The HPV vaccination rate was 44.70%,and the vaccination rate was the highest in the the age group of 20-<30 years old,at 50.8%（95%CI：45.6%-56.0%）,and the lowest in the age group of 60-<70 years old. There was a statistically significant differences in HPV vaccination rate among different age groups（P<0.05）. The analysis of factors affecting HPV vaccination showed that the HPV vaccination rate was higher in those who were younger,living in urban areas,married,with higher education level and higher annual household income（all P<0.05）. However,family history of cervical cancer,history of genital tract inflammation and history of HPV infection were not factors affecting HPV vaccination（all P>0.05）. Conclusion The HPV vaccination rate was low among women in Longgang District of Shenzhen. Health education and related policy support should be strengthened in the subsequent promotion of HPV vaccination among women with lower education level and lower income.

Key words: Human papillomavirus vaccine, Vaccination rate, Community women, Influencing factor

CLC Number:

R186

CAI Songtao, LIANG Wentao, LIN Jinbo, HUANG Xianghui, HONG Guoqin. Analysis of the current status and influencing factors of human papillomavirus vaccination among community women in Longgang District of Shenzhen. [J]OCCUPATION AND HEALTH, 2025, 41(15): 2042-2046.

References

[1] BUSKWOFIE A,DAVID-WEST G,CLARE C A.A review of cervical cancer:Incidence and disparities[J].J Natl Med Assoc,2020,112(2):229-232.
[2] EM B.Human papillomavirus and cervical cancer[J].Clin Microbiol Rev, 2003,16(1):1-17.
[3] VU M,YU J,AWOLUDE O A,et al.Cervical cancer worldwide[J].Curr Probl Cancer,2018,42(5):457-465.
[4] 王秀英,崔芹,韩利伟,等.高危型人乳头瘤病毒感染与宫颈上皮内瘤变的相关性[J].中华医院感染学杂志,2024,34(8):1222-1226.
[5] 卢林丽,方佳琦,阴建,等.人乳头瘤病毒疫苗的研究现状与展望[J].中国肿瘤,2024,33(2):153-160.
[6] WORLD MEDICAL ASSOCIATION.World medical association declaration of Helsinki:Ethical principles for medical research involving human subjects[J].JAMA,2013,310(20):2191-2194.
[7] 陈慧,张荣,刘春容,等.我国西部地区城市和农村中学生对人乳头瘤病毒及其预防性疫苗的认知及态度调查[J].现代预防医学,2020, 47(13):2400-2404.
[8] SIMMS K T,STEINBERG J,CARUANA M,et al.Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries,2020-99:A modelling study[J].Lancet Oncol,2019,20(3):394-407.
[9] 田国良,郝雨欣,王继伟.人乳头瘤病毒疫苗的研究现状及接种政策[J].上海预防医学,2024,36(3):297-302.
[10] PITISUTTTHUM P,VELICER C,LUXEMBOURG A.9-Valent HPV vaccine for cancers,pre-cancers and genital warts related to HPV[J].Expert Rev Vaccines,2015,14(11):1405-1419.
[11] 罗雅娟,王丹丹,杨清.HPV致女性生殖道疾病及HPV疫苗现况[J].国际生殖健康/计划生育杂志,2019,38(3):244-248.
[12] 宋祎凡,刘晓雪,尹遵栋,等.2018—2020年中国9~45岁女性人乳头瘤病毒疫苗估算接种率[J].中国疫苗和免疫,2021,27(5):570-575.
[13] OLIVER K,FRAWLEY A,GARLAND E.HPV vaccination:Population approaches for improving rates[J].Hum Vaccin Immunother,2016, 12(6):1589-1593.
[14] PRABHU V S,BANSAL N,LIU Z,et al.HPV vaccination uptake and administration from 2006 to 2016 in a commercially insured population of the United States[J].BMC Public Health,2021,21(1):1-9.
[15] GOPALANI S V,JANITZ A E,BURKHART M,et al.HPV vaccination coverage and factors among american indians in cherokee nation[J].Cancer Causes Control,2023,34(3):267-275.
[16] 张雨晴,姜晓红,吴江平,等.江苏省南京市1 724例孕前女性HPV疫苗接种现状及其影响因素分析[J].中国妇幼卫生杂志,2022, 13(6):30-34.
[17] LI S L,LAU Y L,LAM T H,et al.HPV vaccination in Hong Kong:Uptake and reasons for non-vaccination amongst Chinese adolescent girls[J].Vaccine,2013,31(49):5785-5798.
[18] ARBYN M,WEIDERPASS E,BRUNI L,et al.Estimates of incidence and mortality of cervical cancer in 2018:A worldwide analysis[J].Lancet Glob Health,2020,8(2):e191-e203.
[19] CHRYSOSTOMOU A C,STYLIANOU D C,CONSTANTINIDOU A,et al.Cervical cancer screening programs in europe:the transition towards HPV vaccination and population-based HPV testing[J].Viruses,2018, 10(12):729-764.
[20] WASER M,HEISS R,BORENA W.Factors affecting children's HPV vaccination in Austria:Evidence from a parent survey[J].Hum Vaccin Immunother,2022,18(6):e1-e11.
[21] SMITH M A,HALL M,LEW J B,et al.Potential for HPV vaccination and primary HPV screening to reduce cervical cancer disparities:Example from New Zealand[J].Vaccine,2018,36(42):6314-6324.
[22] 袁丽,储爱琴,徐安岚,等.育龄女性人乳头瘤病毒疫苗预防接种现状及影响因素分析[J].国际生殖健康/计划生育杂志,2020,39(3):210-212.
[23] 罗丽红,张海燕,钟洁.广东省惠东县女性宫颈癌认知及HPV疫苗接种现状分析[J].中国卫生工程学,2021,20(1):73-75.
[24] 程冉冉. 邯郸市适龄期女性HPV疫苗认知情况和接种现状调查研究[J].科技风,2021(4):148-149.
[25] 刘捷宸,吴琳琳,白庆瑞,等.上海市2017—2019年人乳头瘤病毒疫苗接种率和疑似预防接种异常反应监测[J].中国疫苗和免疫,2020, 26(3):322-325,348.
[26] 张师前,王凯,张远丽.HPV疫苗在中国的应用现状[J].中国实用妇科与产科杂志,2019,35(10):1090-1095.
[27] SIMMS K T,STEINBERG J,CARUANA M,et al.Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries,2020-99:A modelling study[J].Lancet Oncol,2019,20(3):394-407.
[28] MCCORMACK P L.Quadrivalent human papillomavirus(types 6,11,16, 18) recombinant vaccine(gardasil^®):A review of its use in the prevention of premalignant anogenital lesions,cervical and anal cancers,and genital warts[J].Drugs,2014,74(11):1253-1283.
[29] NTANASIS-S I,KYRIAZOGLOU A,LIONTOS M,et al.Current trends in the management and prevention of human papillomavirus(HPV) infection[J].J BUON,2020,25(3):1281-1285.
[30] GRAVITT P E,WINER R L.Natural history of HPV infection across the lifespan:Role of viral latency[J].Viruses,2017,9(10):267-277.